NEW YORK (LPC/Reuters) - Creditors of Valeant Pharmaceuticals International , which has been in violation of lender agreements since Wednesday, are beginning to demand new terms that could further pressure the drugmaker's business model, according to three people familiar with the matter.
Read more
No comments:
Post a Comment